Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 14 March 2018, 11:16 HKT/SGT

Source: Eisai
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China

TOKYO, Mar 14, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary Eisai China Inc. has launched the gastrointestinal prokinetic agent Cidine in China.

Cidine is a gastrointestinal prokinetic agent discovered by Almirall, S.A. Under the terms of a license agreement signed with Almirall in March 2010, Eisai obtained from Almirall the exclusive rights to develop, manufacture and market the agent in China. Eisai obtained approval for the agent in China for the indication to improve the symptoms of early satiety, postprandial fullness discomfort and abdominal bloating for mild-to-moderate functional dyspepsia.

By acting upon the serotonin 4 (5-HT4) receptors of the nerve plexus in the alimentary tract, Cidine increases the release of acetylcholine, and its mild antidopaminergic activity also stimulates the release of acetylcholine and contributes to the therapeutic effect. Acetylcholine increases motor and secretory activity throughout the digestive system, thereby improving gastrointestinal function.

The Chinese pharmaceutical market is the second largest market in the world after the United States, and in 2015 was worth US$115.2 billion (approximately 12.2 trillion yen) and growing at a rate of 7% on a local currency basis, maintaining high growth.1 Eisai considers China as a key region for driving its global business and is working to expand business that addresses not only its global areas of therapeutic focus, but also its franchise tailored to the local disease structures in China. Gastrointenstinal franchise is one such area, and the launch of Cidine will further strengthen the Company's existing gastrointestinal product portfolio together with the currently marketed proton pump inhibitor Pariet, gastritis/gastric ulcer treatment Selbex and hepatic disease/allergic disease agents Stronger Neo-Minophagen C and Glycyron Tablets.

Through the launch of Cidine, Eisai seeks to make further contributions to address the diversified needs of and increase the benefits provided to patients suffering from gastrointestinal diseases in China.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed.

The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenues in 2016 were 859.3 million euros and more than 2,000 employees are devoted to Science.

For more information, please visit,

History of Eisai's Business in China

Eisai has been conducting business in China for over 25 years. Eisai expanded into the market in 1991 through a joint venture company, and in 1996, established Eisai China Inc. (Suzhou, Jiangsu Province), a 100% subsidiary with manufacturing / marketing capabilities. In 2010, Eisai (Suzhou) Trading Co., Ltd. was established for directly importing products and in December 2015, Eisai entered the generic pharmaceutical business in China by buying out Eisai (Liaoning) Pharmaceutical Co., Ltd. for the purpose of providing a stable supply of high-quality generic medicine to fulfil the medical needs of Chinese patients. These three companies were consolidated under Eisai China Holdings Ltd, which was established in December, 2014. The core products of Eisai's Chinese business include peripheral neuropathy treatment Methycobal, liver disease/allergic disease agents Stronger Neo-Minophagen C / Glycyron tablets, anti-Alzheimer's agent Aricept, proton pump inhibitor Pariet, gastritis/gastric ulcer treatment Selbex, and Parkinson's disease treatments Comtan, Stalevo and Eldepryl as well as the pipeline product branched-chain amino acid formula Livact Granules.

(1) Copyright 2018 IQVIA., IMS World Review Executive 2016, reproduction prohibited

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.

Mar 14, 2018 11:16 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech, HealthCare
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Feb 27, 2018 09:33 HKT/SGT
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Feb 21, 2018 08:25 HKT/SGT
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Feb 16, 2018 07:34 HKT/SGT
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Feb 12, 2018 09:03 HKT/SGT
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Feb 1, 2018 16:20 HKT/SGT
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Jan 22, 2018 09:51 HKT/SGT
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Jan 20, 2018 18:32 HKT/SGT
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
Jan 19, 2018 13:35 HKT/SGT
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: